← Back to all trials
Recruiting
NCT07309107
Deep Learning on Amyloid Positons Emission Tomography
Conditions: Alzheimer Disease
Sex: All
Ages: 18 Years – 99 Years
Enrollment: 40
Sponsor: Central Hospital, Nancy, France
Location: CHRU NANCY Brabois, nuclear medicine department Vandœuvre-lès-Nancy
Summary
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \[18F\]flutemetamol.
Eligibility Criteria
Inclusion Criteria:
* Patients with objective cognitive impairment,
* Referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,
Exclusion Criteria:
* Patient have objected to the use of their data.
Source: ClinicalTrials.gov (NCT07309107). StuddyBuddy aggregates publicly available trial information.